Summary: Recently, we developed a method for assessing in vivo drug metabolism capacity by pharmacokinetic estimation of the quantity of cytochrome P450 (CYP) in vivo (PKCYP-test), in which an apparent liver-to-blood free concentration gradient in vivo (qg) is introduced. The qg value can be alternatively deˆned as the ratio of the in vivo-in vitro clearance by a single CYP isoform. In this study, we examined the application of the PKCYP-test to drugs metabolized by multiple CYP isoforms in a rat model with ‰uctuating CYP1A2 levels using theophylline as a model drug.
Introduction
In order to select the most appropriate drug dosage regimens, it is important to predict the drug clearance rate for individual patients. Since a number of isoforms of cytochrome P450 (CYP) exist in human liver for each individual CYP isoform, a drug mainly metabolized by a single isoform is used as a probe for``metabolic diagnosis''. 1) Clinically, it is necessary to estimate the drug clearance rate over a several-fold range, but the use of probe-based assays for measuring the in vivo activity of CYP is often limited to the identiˆcation of patients who are poor or extensive metabolizers due to a genetic polymorphism.
Recent advances in molecular cloning and expression technology have enabled us to use the commercially available cDNA-expressed CYP isoforms, and these heterologously expressed enzymes are being increasingly used as in vitro models of human liver microsomes in quantitative phenotyping.
2) Several approaches have been used to predict in vivo drug metabolisms, such as scaling of in vivo metabolic clearance from in vitro data obtained from human liver microsomes or a recombinant system of human CYP isoforms. 3) In order to improve the correlation between in vitro and in vivo metabolic clearance, some new methods have been described. For example, the ratio of in vivo to in vitro intrinsic clearance has been introduced as a scaling factor 4) and the use of the unbound fraction in liver microsomes has also been examined. 5) However, the reported methods may not adequately predict in vivo drug disposition from in vitro metabolic parameters, and the detailed signiˆcance of the scaling factor remains to be clariˆed.
From a pharmacokinetic point of view, one possible explanation for a scaling factor is that the free concentration in the hepatic vein is used in place of the actual concentration of drug in the liver when the in vivo clearance is estimated using in vitro parameters. In previous work, we described a new method for assessing drug metabolism capacity based on a pharmacokinetic estimation of the quantity of CYP in vivo (PKCYP-test). [6] [7] [8] In setting up the PKCYP-test, an apparent liver-toblood free concentration gradient in vivo (qg) was introduced. Our hypothesis is that the in vivo metabolic clearance of many drugs in patients may be predicted by measuring the quantity of metabolizing enzyme in the liver of individual patients, taking account of the qg (see Appendix) . We have already demonstrated that in rats with ‰uctuating CYP levels, the amount of CYP1A2 6) or CYP2C11 8) could be predicted by the PKCYP-test using the qg values of age-matched control rats. Since several CYP isoforms are involved in in vivo drug metabolism, it is necessary to evaluate the usefulness of the PKCYPtest in the case of multiple CYP isoforms. In order to apply the PKCYP-test to those drugs, it is important to determine the diŠerence in qg values: 1) of each CYP isoform, 2) based on the in vitro intrinsic clearance from liver slices and recombinant CYP, and 3) for a ‰uctuating CYP protein content in vivo.
It has been reported that theophylline is metabolized by multiple CYP isoforms, 9) and theophylline metabolism is known to be increased by 3-methylcholanthrene (MC) treatment of rats, whose CYP1A2 level was elevated. 10) In the present study, using theophylline as a model drug, we examined the application of the PKCYP-test to a drug that is metabolized by multiple CYP isoforms, including CYP1A2. We used a rat model with ‰uctuating CYP1A2 levels.
Moreover, previously, we constructed a physiologically-based pharmacokinetic model which involved the PKCYP-test. 8) By using the qg and the observed amount of CYP2C11 as an indicator of hepatic metabolism capacity, the time-course of tolbutamide concentrations in rat models with ‰uctuating CYP2C11 levels could be predicted. In this study, we also tried to predict the time-course of theophylline concentrations in rats using qg and the observed amount of CYP1A2.
Methods
Materials: Chemicals were obtained from the following sources: theophylline was from Wako Pure Chemicals (Osaka, Japan); MC, 1-methylxanthine (1-MC), 3-methylxanthine (3-MC), 1, 3-dimethyluric acid (1, 3-DMU), 1, 3, 7-trimethyluric acid (1, 3, 7-TMU), b-hydroxyethyltheophylline, goat serum, and rabbit serum were from Sigma Chemical Co. (St. Louis, MO, U.S.A.); [8- 14 C] theophylline was from America Radiolabeled Chemicals, Inc. (St. Louis, MO, U.S.A.); NADPH was from Oriental Yeast Co. (Tokyo, Japan); and microsomal preparations of recombinant rat CYP1A2 expressed by baculovirus-infected insect cells (recombinant rat CYP1A2), Anti-Rat CYP1A1 (anti-rat CYP1A1 antibody), Anti-Rat CYP1A2 (anti-rat CYP1A antibody), and Anti-Rat CYP3A2 (anti-rat CYP3A2 antibody) were from Daiichi Pure Chemicals Co. (Tokyo, Japan). Anti-rat CYP1A antibody inhibited both CYP1A1 and CYP1A2 activity. All other reagents were of reagent grade or HPLC grade and were used without further puriˆcation.
Animals: Male Sprague-Dawley rats, 6 weeks of age, were purchased from Japan SLC, Inc. (Shizuoka, Japan). The rats were pretreated with MC (25 mg W kg, dissolved in olive oil, i.p. daily for 3 days) (MC-treated rats). 6) Control animals were used without pretreatment. The animal experiments were performed in accordance with the Guidelines for Animal Experiments of Kyoritsu College of Pharmacy.
In vivo pharmacokinetic studies: The control and MC-treated rats were given theophylline (1 mg W kg, dissolved in saline) by intravenous injection. Blood was collected from the jugular vein, and the liver was resected. Blood was centrifuged at 15000×g (MX-150, Tomy Seiko Co., Ltd., Tokyo, Japan) for 10 min at 49 C to obtain serum. Serum and liver were stored at "20 and "809 C, respectively, until assayed. To determine the urinary elimination of theophylline, the urine was collected at 24 and 48 hr following theophylline injection. After each collection interval, the volume was measured and the urine centrifuged at 700×g (RLX-105, Tomy Seiko Co., Ltd., Tokyo, Japan) for 10 min at 49 C. The supernatant was stored at "209 C until assayed.
Determination of serum protein binding of theophylline: Theophylline solution was added to the serum to give concentrations of 0, 1, 2, 4, 6, 8, or 10 mg W mL (in a total volume of 800 mL). The serum samples were incubated for 30 min at 379 C. Then, to separate the free fraction from the protein-bound fraction, 700 mL of each serum sample was transferred to a centrifuge tube (Centrifree, Amicon, Inc., Beverly, MA, U.S.A.) and centrifuged at 1000×g for 10 min at 379 C. Following this, 100 mL of the free fraction was obtained and stored at "209 C until analysis; 100 mL aliquots of serum samples containing protein-bound and free drug were also stored at "209 C until assayed.
Quantitation of CYP1A2 and CYP3A2 in liver microsomes: Liver microsomes were prepared as previously described.
11) Quantitation of CYP1A2 6) and CYP3A2 in liver microsomes was performed by Western blotting. The liver microsomes of the control (0.2-0.6 mg proteinW lane) rats were separated by SDSpolyacrylamide gel electrophoresis using 10z gels. Microsomes from male rats with known amounts of CYP3A2 were also applied (0.018-0.064 pmol W lane) as a standard. The separated proteins were transferred to a nitrocellulose membrane which was then incubated with antibodies. Anti-rat CYP3A2 from goat (Daiichi Pure Chemicals Co., Tokyo, Japan) was used as theˆrst antibody. The second antibody was anti-goat IgG peroxidase conjugate, developed in rabbit (Sigma Chemical Co., St. Louis, MO, U.S.A.). The peroxidase activity of the immunoblots was monitored using an enhanced chemilumineacence kit (Amersham, Aylesbury, UK), and the nitrocellulose membrane was exposed to photographicˆlm (Hyper ECL, Amersham, Aylesbury, UK) for 20 sec. The CYP3A2 protein band on theˆlm was quantiˆed densitometrically with an electrophoresis documentation and analysis system (Eastman Kodak, Rochester, NY, U.S.A.), and the CYP3A2 content was determined from a standard curve generated using microsomes from rats treated with phenobarbital. A standard curve was obtained by plotting the intensity of the band on aˆlm on the ordinate axis versus the respective quantity of rat CYP3A2 on the abscissa. The conversion of the amount of CYP3A2 per kg body weight was achieved using a value of 1.09±0.02 g microsomal protein W kg body weight.
6) The conversion of the amount of CYP1A2 per kg body weight in control and MC-treated rats was achieved using values 1.09±0.02 and 1.22±0.06 g microsomal protein W kg body weight, respectively.
6)
Inhibitory eŠect of anti-rat CYP1A1, CYP1A, and CYP3A2 antibodies on metabolism of theophylline in liver microsomes: The assay mixture for theophylline metabolism contained 13.5 mM [8- The speciˆc activity of [8- 14 C] theophylline was adjusted to 1887 Bq W nmol by dilution with unlabeled theophylline. Control and MC-treated rat liver microsomes (0.125 and 0.025 mg, respectively) were preincubated with 50 mL anti-rat CYP1A1, CYP1A, or CYP3A2 antibody for 30 min at room temperature prior to the measurement of theophylline metabolite formation. Under these conditions, the CYP1A1, CYP1A, or CYP3A2 activity of all microsomes, irrespective of their origin, was maximally inhibited. Control incubations contained an equivalent amount of preimmune goat (for CYP1A1) or rabbit (for CYP1A and CYP3A2) serum proteins. Then, the assay mixture without [8- 14 C] theophylline was added and preincubation was carried out in a shaking bath for 10 min (for control rats) or 20 min (for MC-treated rats) at 379 C. The reaction was started by the addition of [8- 14 C] theophylline and incubation was carried out in a shaking bath for 20 min (for control rats) or 15 min (for MC-treated rats) at 379 C. The reaction was halted by the addition of 100 mL 20z perchloric acid, and the radioactivity due to each of the theophylline metabolites was measured. Then, the z of control activity was calculated. Since the inhibitory capacity of anti-rat CYP1A1 antibody towards CYP1A1 was 65z, the activities which were inhibited by anti-rat CYP1A1 antibody were corrected using this value. The contribution of each CYP isoform ( fCYP) was calculated from the z of control activity. In case where the z of control activity was more than 100z, the fCYP was taken as zero.
Determination of Michaelis constant (Km) and maximal rate of metabolism (Vmax) for theophylline metabolism by recombinant rat CYP1A2: The assay mixture for theophylline metabolism contained 4.86 pmol of recombinant rat CYP1A2, [8- 14 C] theophylline (12.5, 25, 50, 75, 100 mM), 0.4 mM NADPH, 0.67 mg W mL MgCl2 ・6H 2 O, and 25 mM Tris buŠer (pH 8.0) in aˆnal volume of 0.5 mL. The speciˆc activity of [8- 14 C] theophylline was adjusted to 1887 Bq W nmol by dilution with unlabeled theophylline. The assay mixture without [8- 14 C] theophylline was preincubated in a shaking bath for 10 min at 379 C. The reaction was started by the addition of [8- 14 C] theophylline, and incubation was carried out in a shaking bath for 20 min at 379 C. The reaction was halted by the addition of 100 mL 20z perchloric acid, and the radioactivity due to each of the theophylline metabolites was measured.
Assay of theophylline and its metabolites: Theophylline in serum, liver, and urine was assayed by HPLC, using a modiˆcation of the reported procedures. 12, 13) Brie‰y, 10 mL 20 mg W mL 1, 3, 7-TMU (internal standard), 100 mL 1 N perchloric acid were added to 100 mL serum followed by vortexing and centrifugation at 15000×g for 10 min at 49 C. The supernatant was passed through a 0.45-mmˆlter (4 mm Millex-LH, Nihon Millipore Ltd., Tokyo, Japan), and 60 mL was subjected to HPLC. The liver was homogenized in an equal weight of distilled water. Then, 10 mL 20 mg W mL 1, 3, 7-TMU (internal standard) and 200 mL 1 N perchloric acid were added to 200 mL homogenate. The sample was then treated in the same way as serum. 200 mL 1 M sodium acetate buŠer (pH 5.0), 10 mL 80 mg W mL b-hydroxyethyltheophylline (internal standard), and 9 mL methylene chloride were added to 200 mL urine followed by vortexing and centrifugation at 700×g for 5 min at room temperature. The methylene chloride phase was evaporated. Then, the organic layer was removed and transferred to a fresh tube and dried at 409 C under nitrogen. Each sample was resuspended in 200 mL HPLC mobile phase, passed through a 0.45-mmˆlter, and 30 mL was subjected to HPLC. A calibration curve was constructed by spiking drug-free rat serum, liver homogenate, and urine with concentrated theophylline solution to give solutions of 0, 0.25, 0.5, 1, 2, and 4 mg W mL (for serum and liver homogenate) or 0, 0.25, 0.5, 1, 2, 4, and 8 mg W mL (for urine). Samples were submitted to the extraction procedure described above and a calibration curve was ob-tained by plotting the peak-area on the ordinate axis versus the respective drug concentrations on the abscissa. The HPLC system consisted of a pump (Programmable pump Model 307, Gilson, Middleton, WI), an autoinjector (Model 234, Gilson, Middleton, WI), a variable wavelength UV detector (Programmable detector Model 118 (UV W VIS), Gilson, Middleton, WI), a recorder (Chromatocorder 21, System Instruments, Tokyo, Japan), and a column oven (655A-52 column oven, Hitachi, Tokyo, Japan). Separation was achieved on a C18 reversed-phase column (250 mm×4.6 mm i.d., particle size 5 mm, Capcell Pak C18 UG120 S-5 mm, Shiseido, Tokyo, Japan) at a column temperature of 409 C. The mobile phase consisted of 22 mL: 1.25 mL: 175 mL: 463 mL acetonitrile: tetrahydrofuran: acetic acid: water, at a ‰ow rate of 0.8 mL W min, and the column eluate was monitored at 280 nm. The retention times for theophylline, b-hydroxyethyltheophylline, and 1, 3, 7-TMU were 17.6, 24.1, and 25.0 min, respectively. The lower limit of quantiˆcation was 0.25 mg W mL.
To measure the radioactivity of theophylline metabolites in the samples from the in vitro theophylline metabolism and the inhibition studies of in vitro theophylline metabolism, the metabolites wereˆrst separated by HPLC. 10 mL 50 mg W mL 3-MC, 1-MC, and 1, 3-DMU (internal standard) were added to each sample, followed by vortexing and centrifugation at 15000×g (M200-IVD, Sakuma, Tokyo, Japan) for 5 min at 49 C. The supernatant wasˆltered through a 0.45-mmˆlter and 400 mLˆltrate was subjected to HPLC. The HPLC conditions were as follows: instruments, a Shimadzu LC-9A liquid chromatograph equipped with a SPD-6A spectrophotometoric detector, a SCL-6B system controller, a data processor (Chromatopac C-R4A), and a CTO-6A column oven; the HPLC column used was the same as that for the analysis of the theophylline in serum, liver, and urine; column temperature, 409 C; the mobile phase was consisted of 5:95 (v W v) acetonitrile: 10 mM acetic acid (adjusted to pH 4.0 with NH4OH); ‰ow rate, 1.0 mL W min; the absorbance wavelength was set at 280 nm. The retention times for 3-MC, 1-MC, 1, 3-DMU, and theophylline were 6.3, 6.6, 9.0, and 15.4 min, respectively. Each metabolite fraction was mixed with 5 mL Clear-sol I (Nacalai Tesque, Kyoto, Japan) and counted using a liquid scintillation counter (Beckman LS 5801, Beckman Instruments, U.S.A.).
Estimation of the qg values of theophylline for CYP1A2 and CYP3A2 based on the Km and Vmax values for liver slices from control rats: The hepatic clearance (CL h ) in control rats was used to estimate the qg value of theophylline. The intrinsic metabolic clearance (CLint) can be expressed by CLh, the unbound fraction of drug in serum ( fp), and the hepatic blood ‰ow rate (Qh), 14) as follows:
Then, the qg value of theophylline based on the in vitro intrinsic clearance determined using liver slices was estimated according to Eq. (A5) as follows:
where CLint,vitro is the in vitro intrinsic clearance. In addition, for each CYP isoform, the intrinsic clearance can be obtained by multiplying the fCYP by the apparent CLint. Therefore, the qg value of theophylline for CYP1A2 and CYP3A2 in control rats was estimated according to Eq. (A6) as follows:
Estimation of the qg values of theophylline for CYP1A2 based on the Km and Vmax values for recombinant CYP1A2 in control and MC-treated rats: The qg values of theophylline for CYP1A2 based on the Km and V max values for recombinant CYP1A2 in control and MC-treated rats were estimated according to Eq. (A6).
Analysis using a physiologically-based pharmacokinetic model 8) : The physiologically-based pharmacokinetic model which introduced the PKCYP-test was used. In this model, Eq. (3) was introduced as the hepatic intrinsic clearance (CLint,lv).
CLint,lv＝
Vmax,vitro
Where A-CYPvivo is the in vivo amount of CYP and CL,f is the free concentration (not bound to macromolecules) of drug within the hepatic vein. Km,vitro is the in vitro Michaelis constant for the drug-enzyme interaction and Vmax,vitro is the in vitro maximal rate of metabolism. The mean of the physiological data from the literature [15] [16] [17] was used for the blood ‰ow rate (Q) and tissue volume (Vd) parameters of each organ in the model. The reported values of the blood-to-plasma concentration ratio (Rb) and the tissue-to-plasma partition coe‹cient (Kp) for theophylline were also used.
18) The mass balance equation for the concentration in each organ compartment was solved simultaneously by the RungeKutta-Gill method as described in the literature, 19) and the concentration in serum after a single intravenous administration was calculated.
Data analysis: Serum concentration versus time data were analyzed by model-independent moment analysis. The last determined serum concentration was extrapolated to inˆnity using the terminal slope of the last two points of the log serum concentration-time curve. The volume of distribution at steady-state (Vd,ss) and the total body clearance (CLtot) were estimated as described by Yamaoka et al. 20) The apparent tissue-toplasma concentration ratio of free drug (Kpf,app) for theophylline was obtained by dividing the liver concentration by the free concentration in serum. Data were analyzed using Student's t test for comparison of unpaired means of two sets of data. Analysis of variance was used to compare more than two sets of data. The number of determinations (n) is noted in the table. A p value of 0.05 or less was used to indicate a signiˆcant diŠerence between sets of data.
Results
Comparison of the pharmacokinetics of theophylline in control and MC-treated rats: In order to estimate the qg values, the theophylline clearance in control and MC-treated rats was investigated. The serum concentration versus time proˆles of theophylline in control and MC-treated rats are shown in Fig. 1 . Since the theophylline proˆle suggests linear pharmacokinetics, the CLtot was determined under linear conditions. The results of linear model-independent moment analysis are given in Table 1 . The CLtot of theophylline in MC-treated rats was approximately 7-fold larger than that of control rats. Since in control and MC-treated rats, approximately 30 and 6z unchanged theophylline is eliminated in the urine, respectively, the CLh was corrected by using the fraction of the dose excreted unchanged in urine.
Then, the CLh of theophylline in MC-treated rats was about 10-fold larger than that of control rats ( Table 1) .
The physiological data for the theophylline-treated rats used in this study is also summarized in Table 1 . There were some diŠerences in body weight between control and MC-treated rats. There were no signiˆcant diŠerences in the fp and the Kpf,app. The Vd,ss of MCtreated rats was slightly larger than that of control rats.
Estimation of the contribution of CYP1A2 and CYP3A2 to the liver microsomal metabolic activity for theophylline in control and MC-treated rats: The contribution of CYP1A2 and CYP3A2 to liver microsomal theophylline metabolism in control and MC-treated rats was estimated using anti-rat CYP1A1, CYP1A, and CYP3A2 antibodies. The eŠects of these antibodies on theophylline liver microsomal metabolism in control and MC-treated rats are shown in Table 2 . Control activity in the presence of preimmune serum in control and MC-treated rats was 0.68±0.23 and 5.16± 0.97 pmol W min W mg, respectively. As shown in Table 2 , the contribution of CYP1A2 to liver microsomal theophylline metabolism in MC-treated rats was slightly greater than that of control rats. In control rats, liver microsomal theophylline metabolism was mainly catalyzed by CYP3A2.
Estimation of the qg values of theophylline for CYP1A2 and CYP3A2 based on the Km and Vmax values for liver slices from control rats: The qg value of theophylline based on the in vitro intrinsic clearance determined using liver slices was estimated as 7.80 using parameters listed in Tables 1 and 3 .
In addition, the qg values of theophylline for In vitro maximal rate of metabolism.
d The conversion of CL int,vitro per kg body weight was achieved using 11.0 g liver W 250 g body weight. The conversion of CL int,vitro per kg body weight was achieved using the in vivo amount of CYP1A2 listed in Table 1 .
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Simultaneous Assessment of In Vivo CYP by the PKCYP-test CYP1A2 and CYP3A2 in control rats were estimated as 7.77 and 7.80, respectively using parameters listed in Tables 1 and 3 . Hence, the qg value of theophylline estimated from the total hepatic intrinsic clearance was comparable with both qg values estimated from the hepatic intrinsic clearance mediated by CYP1A2 and CYP3A2.
Estimation of the qg values of theophylline for CYP1A2 based on the K m and V max values for recombinant CYP1A2 in control and MC-treated rats: In order to estimate the qg value for each CYP isoform, the Km and Vmax values for theophylline metabolism by recombinant CYP1A2 were determined. Conversion of theophylline to 1-MC, 3-MC, and 1, 3-DMU by recombinant CYP1A2 exhibited Michaelis-Menten kinetics. The Lineweaver-Burk plot shown in Fig. 2 was used to derive the Km and Vmax values for recombinant CYP1A2 ( Table 4) . The qg values of theophylline for CYP1A2 based on the Km and Vmax values for recombinant CYP1A2 in control and MC-treated rats were estimated as 9.35 and 7.14, respectively using the parameters listed in Tables 1 and 4 . Hence, they were almost identical. Furthermore, there was no diŠerence between the qg value for CYP1A2 in control and MC-treated rats.
Prediction of time-courses of theophylline concentrations in control and MC-treated rats: The theophylline concentration-time proˆles in serum, following intravenous administration of theophylline to control and MC-treated rats at a dose of 1 mg W kg, were estimated using the physiologically-based pharmacokinetic model which involved the PKCYP-test. As shown in Fig. 3 , by introducing the qg of control rats based on the Km and Vmax values for recombinant CYP1A2 and the observed amount of CYP1A2 as an indicator of hepatic metabolism capacity, the theophylline concentrationtime proˆles in serum from control and MC-treated rats could be simulated. In control and MC-treated rats, the predicted theophylline concentrations were within the 95z conˆdence interval of the observed theophylline concentrations.
Discussion
In the present study, we examined the application of the PKCYP-test to drugs metabolized by multiple CYP Fig. 3 . Predicted and observed log theophylline concentrations after intravenous administration of a dose of 1 mg W kg to control and MCtreated rats. MC-treated rats were pretreated with MC as described in Fig. 1 isoforms using theophylline as a model drug. We focused attention on the diŠerence in qg values: 1) of each CYP isoform, 2) based on the in vitro intrinsic clearance from liver slices and recombinant CYP, and 3) for a ‰uctuating CYP protein content in vivo. We constructed a physiologically-based pharmacokinetic model which introduced the PKCYP-test.
Firstly, we examined the pharmacokinetics of theophylline in control and MC-treated rats. The CLtot and CLh of theophylline in MC-treated rats were about 7-fold and 10-fold larger than that of control rats ( Table 1) . The CL tot of theophylline in control rats was linearly related to dose and agreed well with the previously reported value.
12) The CLh of theophylline in control rats agreed well with the previously reported value. 12) Secondly, we estimated the contribution of CYP1A2 and CYP3A2 to liver microsomal theophylline clearance in control and MC-treated rats, and examined the diŠer-ence in the qg value of each CYP isoform. Theophylline metabolism is reported to be catalyzed by CYP1A2 in rats. 21) Moreover, it has been reported that another CYP isoform in rats, such as CYP3A2, a male-speciˆc CYP isoform, 22) is also involved in the metabolism of theophylline. 10) We also examined the eŠect of anti-rat CYP2C11 antibody on theophylline liver microsomal metabolism in control rats, which is also a male-speciˆc CYP isoform in rats, 22) although no inhibitory eŠect was observed in control rats (data not shown). The fCYP for CYP1A2 and CYP3A2 with respect to liver microsomal theophylline metabolism in control rats was 0.25 and 0.80, respectively ( Table 2) . On the other hand, in MCtreated rats, the fCYP for CYP1A1 and CYP1A2 with respect to liver microsomal theophylline metabolism was 0.31 (data not shown) and 0.39 (Table 2) , respectively. Therefore, liver microsomal theophylline metabolism in MC-treated rats seems to be mediated by more than three CYP isoforms including CYP1A1, CYP1A2, and putatively, CYP3A2.
We estimated the qg values for CYP1A2 and CYP3A2 based on the Km and Vmax values for liver slices in control rats. Notably, the qg values for CYP1A2 and CYP3A2 were almost equal to the qg value which was estimated using the total hepatic intrinsic clearance. These results suggest that the qg values for each CYP isoform are equal in the case of theophylline. Thus, the drug concentration at the enzyme site for each CYP isoform seems to be equal indicating that the assumption for qg, the apparent liver-to-blood free concentration gradient in vivo, is appropriate.
Thirdly, we compared the qg value for CYP1A2 based on the K m and V max values by recombinant CYP1A2 in control and MC-treated rats. It has been reported that the application of the relative activity factor (RAF) for each CYP isoform is needed in mathematically reconstruct the biotransformation rates in liver microsomes using recombinant CYP isoforms. 23) There is a possibility that the qg values estimated using in vitro intrinsic clearance from liver slices and recombinant CYP isoforms are diŠerent for each CYP isoform. In control rats, the qg value for CYP1A2 based on the Km and V max values by recombinant CYP1A2 was similar to that by liver slices. Therefore, in case of theophylline, it seems that there is no signiˆcant diŠerence between the qg values estimated using the in vitro intrinsic clearance from liver slices and recombinant CYP isoforms. Moreover, since the qg value in control and MC-treated rats were also almost identical, it seems that the qg value remains unaltered when CYP levels ‰uctuate. These results are consistent with the observation of a similar Kpf,app of theophylline in liver for control and MC-treated rats ( Table 1 ). All the theophylline qg values estimated in this study were greater than unity. This means that the free concentration of theophylline near CYP may be larger than that in the hepatic vein. However, the Kpf,app of theophylline in both control and MC-treated rats was almost unity (Table 1) . Hence, another reason for this incompatibility may be underestimation of the in vitro intrinsic clearance of theophylline. It has been reported that a correction for free fraction diŠerences between microsomes and plasma improves the predictive utility of microsomal data. 24) In the case of theophylline, there may be free fraction diŠerences between microsomes and plasma, although accurate predictions of hepatic clearance have also been made without the need for such a correction. 5) Thus, further studies are needed to clarify this point.
Fourthly, we evaluated the eŠects of qg and the amount of CYP as an indicator of hepatic metabolism capacity on the time-course of theophylline concentrations in serum using a physiologically-based pharmacokinetic model which introduced the PKCYP-test. The Vd,ss in MC-treated rats was greater than that of control rats ( Table 1) . Since there were no diŠerences in the fp and the Kpf,app between control and MC-treated rats (Table 1) , the reason for this remains unknown. However, one possible explanation is increased distribution into the eliminating organs in MC-treated rats. In both control and MC-treated rats, the simulated values agreed with the observed values (Fig. 3) . Therefore, introduction of the qg and the amount of CYP also seems to be useful in the case of CYP1A2-mediated theophylline metabolism.
In conclusion, we have been able to show that in the case of theophylline, the PKCYP-test was applicable to drugs which are metabolized by multiple CYP isoforms using the qg value and considering the CL int as the sum of the CLint of each CYP isoform. We have also demonstrated that the qg value and the amount of CYP are useful parameters in the PKCYP-test using a physiologically-based pharmacokinetic model which was introduced by the PKCYP-test. However, it is necessary to discover the reasons for the relatively high qg values for the PKCYP-test. If they can be successfully identied, this will help clarify the meanings of the scaling factor, and conˆrm the qg as a useful parameter for the PKCYP-test.
